| Literature DB >> 35696640 |
Chunwei Jiao1,2, Hao Yun1, Huijia Liang1, Xiaodong Lian3, Shunxian Li3, Jiaming Chen1, Javeria Qadir4, Burton B Yang4, Yizhen Xie1,2.
Abstract
The mushroom Ganoderma lucidum is a traditional Chinese medicine and G. lucidum spore oil (GLSO) is the lipid fraction isolated from Ganoderma spores. We examined the effect of GLSO on burn wound healing in mice. Following wounding, GLSO was applied on the wounds twice daily. Repair analysis was performed by Sirius-Red-staining at different time points. Cell proliferation and migration assays were performed to verify the effect of GLSO on growth. Network pharmacology analysis to identify possible targets was also carried out, followed by Western blotting, nuclear translocation, cell proliferation, and immunofluorescence assays for in-depth investigation of the mechanism. Our study showed that GLSO significantly promoted cell proliferation, and network pharmacology analysis suggested that GLSO might act through transient receptor potential vanilloid receptor 1 (TRPV1)/SMAD signaling. Furthermore, GLSO elevated SMAD2/3 expression in skin burn and promoted its nuclear translocation, and TRPV1 expression was also increased upon exposure to GLSO. Cell proliferation and immunofluorescence assays with TRPV1 inhibitor showed that GLSO accelerated skin burn wound healing through TRPV1 and SMADs signaling, which provides a foundation for clinical application of GLSO in the healing of deep skin burns.Entities:
Keywords: Ganoderma lucidum spore oil; network pharmacology; wound healing
Mesh:
Substances:
Year: 2022 PMID: 35696640 PMCID: PMC9320545 DOI: 10.18632/aging.204119
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.955
Figure 1Workflow for GLSO treatment of skin burn injury.
Figure 2The effect of GLSO on the ratio of collagen I to collagen III in skin burn in mice. (A) Sirius Red staining of the sham mouse skin observed using a polarizing microscope. Scale bar=200 μm. (B) Sirius Red staining of the mouse skin treated with or without GLSO. Scale bar=200 μm. (C) Quantitative analysis of the ratio of collagen I to collagen III was performed (n=3 per group). The data are presented as the mean ± SD. *P<0.05 versus sham.
Figure 3The proliferation and migration effects of GLSO on HaCaT cells. (A) Images of HaCaT cell growth with or without GLSO treatment. (B) Quantitative analysis of HaCaT cell proliferation with GLSO at different time points. (C) Images of HaCaT cell migration with or without GLSO treatment. Scale bar, 1 mm. (D) Quantitative analysis of wound closure by HaCaT cell migration with GLSO treatment. The data are presented as the mean ± SD. *P<0.05, **P<0.01 versus control.
Figure 42D structures of the GLSO main ingredients.
Figure 5Network pharmacology analysis of GLSO drug-ingredients’ targets. (A) left, Burn disease-associated molecules; right, Potential targets of GLSO; middle, overlap of left and right. (B) Network analyzer analysis of GLSO drug-ingredients’ targets. (C) GLSO-ingredients-disease-targets network. (D) KEGG analysis of potential GLSO targets.
Figure 6Analysis of SMAD2/3 and TRPV1 expression in mouse skin burn. (A) Western blot (upper) and quantitative analyses (lower) of SMAD2/3 and p-SMAD2/3. (B) Immunofluorescence staining of SMAD2/3 nuclear translocation on LPS (1 μg/mL) induction. Scale bar=200 μm. (C) Immunofluorescence staining of TRPV1 expression in skin burn upon GLSO treatment. Scale bar=200 μm. The data are presented as the mean ± SD. *P<0.05 versus sham.
Figure 7Effect of TRPV1 inhibitor on HaCaT cell proliferation. (A) HaCaT cells were pre-incubated with TRPV1 inhibitor (0.0258 μg/mL) for 3 and 16 h, followed by further incubation with GLSO for 48 h. GLSO-promoted cell proliferation was downregulated by TRPV1 inhibitor. (B) Quantitative analysis of reduced HaCaT cell numbers treated with TRPV1 inhibitor. (C) Immunofluorescence staining for TRPV1 and SMAD2/3 expression treated with TRPV1 inhibitor. Treatment with GLSO increased TRPV1 and SMAD2/3 expression that were down regulated by TRPV1 inhibitor. Scale bar=200 μm. The data are presented as the mean ± SD. *P<0.05, **P<0.01 versus control.